Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 8,146 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Period 1 Clear all

Conditions: Healthy Volunteers
Interventions: Emraclidine, Itraconazole, Carbamazepine, Metformin; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Relapsing Multiple Sclerosis
Interventions: BIIB017, naproxen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 38
States / cities: Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 34 more

Conditions: Myelofibrosis, Primary Myelofibrosis (PMF), Post- Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Interventions: PXS-5505; Drug
Lead sponsor: Syntara; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Birmingham, Alabama • Winston-Salem, North Carolina • Houston, Texas

Conditions: Diabetes Mellitus, Type 1
Interventions: Usual care, Collaborative care model (CoCM); Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Interventions: Incredible Years Program; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 22 Months to 38 Months
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Chelsea, Massachusetts • Dorchester, Massachusetts • Jamaica Plain, Massachusetts + 6 more

Conditions: Healthy Volunteers
Interventions: SHP643; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Nab-paclitaxel, IG-001; Drug
Lead sponsor: Sorrento Therapeutics, Inc.; Industry
Eligibility: 30 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Fayetteville, Arkansas • Chattanooga, Tennessee • Memphis, Tennessee + 1 more

Conditions: Rheumatoid Arthritis
Interventions: ADL5859, Naproxen, Placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 8
States / cities: Trumbull, Connecticut • Daytona Beach, Florida • Wheaton, Maryland + 5 more

Conditions: Childhood Apraxia of Speech
Interventions: Dynamic Temporal and Tactile Cuing; Behavioral
Lead sponsor: New York University; Other
Eligibility: 29 Months to 95 Months
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Low Back Pain
Interventions: Lidoderm®; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 6
States / cities: Birmingham, Alabama • Hueytown, Alabama • Phoenix, Arizona + 3 more

Conditions: Advanced Metastatic Melanoma
Interventions: Cabozantinib, Pembrolizumab; Drug
Lead sponsor: John Rieth; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Poor Quality Sleep
Interventions: Pistachio, Control food; Dietary Supplement
Lead sponsor: Columbia University; Other
Eligibility: 45 Years to 64 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Impairment, Hemodialysis
Interventions: INCB000928; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 82 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 5
States / cities: Rialto, California • Hialeah, Florida • Miami, Florida + 2 more

Conditions: Healthy Volunteers
Interventions: Sumatriptan, PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Kidney Diseases
Interventions: Integrated ambulatory palliative and nephrology care, Standard nephrology care; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Paclitaxel, Gemcitabine, Avastin; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HIV Infections
Interventions: Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms
Interventions: Solriamfetol 150 MG, Placebo; Drug
Lead sponsor: Axsome Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 508 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 40
States / cities: Tucson, Arizona • Bellflower, California • Chino, California + 33 more

Conditions: Primary Hypogonadism, Hypogonadotropic Hypogonadism
Interventions: Testosterone Topical Gel, 1.62% Metered Pump, AndroGel (testosterone gel) 1.62% Metered-Dose Pump; Drug
Lead sponsor: Amneal Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Anemia of Chronic Kidney Disease
Interventions: Cholecalciferol; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 21 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Postoperative Pain
Interventions: Subpleural pain catheter with infusion of 0.125% bupivacaine, Standard acute pain management; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Polycystic Ovarian Syndrome (PCOS), Irregular Menstrual Cycles, Androgen Excess
Interventions: doxycycline, Sugar Pill; Drug · Other
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Atopic Dermatitis
Interventions: APG777; Drug
Lead sponsor: Apogee Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 23
States / cities: Fountain Valley, California • Los Angeles, California • Coral Gables, Florida + 20 more

Conditions: Cataracts, Alzheimer's Disease
Interventions: Immediate Cataract Surgery; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 50 Years to 90 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Cleveland, Ohio

Search by objective public record fields.

A Trial to Evaluate the Effects of Itraconazole and Carbamazepine on the Pharmacokinetics of Emraclidine and of Emraclidine on the Pharmacokinetics of Metformin in Healthy Adult Participants

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017)

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Testing an Integrated Care Model Trial

Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders

A Study to Determine the Bioavailability of Lanadelumab (SHP643) Administered Subcutaneously With the Prefilled Syringe and the Autoinjector in Healthy Adult Volunteer Participants.

Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer

Study Evaluating the Analgesic Efficacy and Safety of ADL5859 in Participants With Rheumatoid Arthritis

A Randomized Control Trial of Motor-based Intervention for CAS

Pilot Study of the Efficacy and Safety of Lidoderm Patch in the Treatment of Low Back Pain

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Impact of Pistachio Consumption on Sleep

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis

A STUDY TO EVALUATE THE EFFECT OF PF-06651600 ON PHARMACOKINETICS OF SINGLE DOSE SUMATRIPTAN IN HEALTHY PARTICIPANTS.

Pilot Randomized-controlled Trial of Integrated Palliative and Nephrology Care Versus Usual Nephrology Care.

A Study of Biweekly Gemcitabine, Paclitaxel, and Avastin in Patients With Metastatic Breast Cancer

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol

Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

Vitamin D as a Modifier of Serum Hepcidin in Children With Chronic Kidney Disease

Continuous Subpleural Infusion of Bupivacaine

Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Cataract Removal and Alzheimer's Disease